These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37978179)

  • 21. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
    Coppola N; Minichini C; Starace M; Sagnelli C; Sagnelli E
    J Med Virol; 2016 Oct; 88(10):1659-71. PubMed ID: 26991255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.
    Palanisamy N; Kalaghatgi P; Akaberi D; Lundkvist Å; Chen ZW; Hu P; Lennerstrand J
    Antivir Ther; 2018; 23(6):485-493. PubMed ID: 29745936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients.
    Khan HU; Khan S; Shah MA; Attaullah S; Malik MA
    PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
    Kiattanaphon A; Vipsoongnern Y; Kunthalert D; Sistayanarain A
    Mol Biol Rep; 2022 Oct; 49(10):9437-9443. PubMed ID: 36002650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
    Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
    Esser-Nobis K; Romero-Brey I; Ganten TM; Gouttenoire J; Harak C; Klein R; Schemmer P; Binder M; Schnitzler P; Moradpour D; Bartenschlager R; Polyak SJ; Stremmel W; Penin F; Eisenbach C; Lohmann V
    Hepatology; 2013 Mar; 57(3):953-63. PubMed ID: 23322644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
    Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
    Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
    Gaudieri S; Rauch A; Pfafferott K; Barnes E; Cheng W; McCaughan G; Shackel N; Jeffrey GP; Mollison L; Baker R; Furrer H; Günthard HF; Freitas E; Humphreys I; Klenerman P; Mallal S; James I; Roberts S; Nolan D; Lucas M
    Hepatology; 2009 Apr; 49(4):1069-82. PubMed ID: 19263475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan].
    Kartashov MY; Svirin KA; Bekbolotov AA; Momusheva KT; Iskanova BM; Solpueva AS; Motorov UT; Narmatova EB; Krivosheina EI; Gladysheva AV; Chub EV; Gashnikova NM
    Vopr Virusol; 2023 Jul; 68(3):265-270. PubMed ID: 37436417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
    Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
    New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.
    Zeminian LB; Padovani JL; Corvino SM; Silva GF; Pardini MI; Grotto RM
    Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):13-7. PubMed ID: 23440108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.
    Khan S; Soni S; Veerapu NS
    Front Cell Infect Microbiol; 2020; 10():325. PubMed ID: 32714881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.